BMAL1 and prostate cancer: The idea that prostate cancer cells can be driven toward androgen independence via the pathway of drug-induced epigenomic plasticity which reprograms circadian rhythm regulation has recently been explored in a phase 2 clinical trial by Linder et al. This study demonstrated that in tissues of patients with high-risk prostate cancer treated with 3 months of enzalutamide monotherapy, there was reprogramming in pioneer factor forkhead box protein A1 (FOXA1), which ultimately led to these FOXA1 sites being enriched for the circadian clock component BMAL1.